# Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

> **NCT03844360** · PHASE4 · RECRUITING · sponsor: **Wei Zhao** · enrollment: 1500 (estimated)

## Conditions studied

- Hematological Neoplasms

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Eltrombopag
- **DRUG:** Imatinib
- **DRUG:** dasatinib
- **DRUG:** Pegaspargase
- **DRUG:** Anti-Infective Drugs
- **DRUG:** PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

## Key facts

- **NCT ID:** NCT03844360
- **Lead sponsor:** Wei Zhao
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-01-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2025-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03844360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03844360, "Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03844360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*